Universitäres Centrum für Tumorerkrankungen Mainz (UCT Mainz)
Klinisch orientierter Schwerpunkt / Johannes Gutenberg-Universität Mainz
Gehrke, Nadine; Biedenbach, Jana; Huber, Yvonne et al.
Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLDSCIENTIFIC REPORTS. Bd. 9. 2019
Pfirrmann, Daniel; Huber, Yvonne; Schattenberg, Joern Markus et al.
Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention StudyJOURNAL OF MEDICAL INTERNET RESEARCH. Bd. 21. H. 1. 2019
Almstedt, K; Hasenburg, A
Wechseljahresbeschwerden – Hormonmangel nach der gynäko-onkologischen TherapieFrauenheilkunde up2date. Bd. 13. H. 5. 2019 S. 475-485
Schmalfeldt, Barbara; Brambs, Christine; Burges, Alexander et al.
What is the evidence for lymphadenectomy in presumed early ovarian cancer?ARCHIVES OF GYNECOLOGY AND OBSTETRICS. Bd. 299. H. 1. 2019 S. 1-5
Theobald, M
Zell- und Gentherapie bei soliden TumorenTumorDiagnostik & Therapie. Bd. 40. 2019 S. 659-662
Wiesmann, Nadine; Kluenker, Martin; Demut, Philipp et al.
Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agentJOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY. Bd. 51. 2019 S. 226-234
Verhoeven, Carole; Schmidt, Marcus; Hoenig, Arnd et al.
(E)stetrol for treatment of advanced ER+ breast cancerCANCER RESEARCH. Bd. 78. H. 4. 2018
Czauderna, C.; Koch, S.; Pilz, L. et al.
A high alpha-fetoprotein slope prior to therapy correlates with poor prognosis of patients with hepatocellular carcinomasJOURNAL OF HEPATOLOGY. Bd. 68. 2018 S. S442-S442
Surowy, Harald; Varga, Dominic; Burwinkel, Barbara et al.
A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (< 60 years) and is associated with reduced DNA repair capacityINTERNATIONAL JOURNAL OF CANCER. Bd. 142. H. 4. 2018 S. 757-768
Kebenko, Maxim; Goebeler, Marie-Elisabeth; Wolf, Martin et al.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE (R)) antibody construct, in patients with refractory solid tumorsONCOIMMUNOLOGY. Bd. 7. H. 8. 2018